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ARTICLE
 Improvement in Histologic Response But Not 
Survival in Osteosarcoma Patients Treated With 
Intensified Chemotherapy: A Randomized Phase III 
Trial of the European Osteosarcoma Intergroup 
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Anne Kirkpatrick,  Esther I.  Hauben,  Alan W.  Craft,  Antonie H. M.  Taminiau  
On behalf of MRC BO06 and EORTC 80931 collaborators and European Osteosarcoma Intergroup 
  Background  Previous randomized controlled trials that used the two-drug chemotherapy regimen of cisplatin and 
 doxorubicin as the conventional arm showed no evidence of benefit from an increase in the number of 
agents or the length of treatment. It was then proposed that survival could be improved by increasing the 
planned dose intensity of cisplatin and doxorubicin. 
  Methods  Previously untreated patients with nonmetastatic, high-grade, central osteosarcoma of an extremity were 
randomly assigned to Regimen-C (conventional treatment with six 3-week cycles of cisplatin [100 mg/m 2 by 
24-hour infusion] and doxorubicin [25 mg/m 2 /day by 4-hour infusion for 3 days]) or to Regimen-DI (intensified 
treatment with identical total doses of cisplatin and doxorubicin, planned as six 2-week cycles supported by 
granulocyte colony stimulating factor (G-CSF). Surgery was scheduled for week 6 in both arms. Primary and 
secondary outcome measures were overall and progression-free survival, respectively. Intention-to-treat analy-
ses were performed using standard survival analysis methods. Landmark analyses were performed in patients 
with known surgical details and centrally reviewed histologic response. All statistical tests were two-sided. 
  Results  Between May 1993 and September 2002, treatment was randomly allocated to 497 eligible patients. Six cycles 
of chemotherapy were completed by 78% of patients in Regimen-C and 80% of patients in Regimen-DI. 
The delivered preoperative median dose intensity of cisplatin was 86% in Regimen-C and 111% in Regimen-DI 
(as the percentage of that planned for the conventional regimen). Postoperative median dose intensity of 
 cisplatin was 82% in Regimen-C and 110% in Regimen-DI (the corresponding figures for doxorubicin dose inten-
sity were similar). Regimen-DI was associated with lower risks of severe leucopenia and neutropenia  and 
higher risks of thrombocytopenia and mucositis. Good histologic response (>90% tumor necrosis) 
was observed in 36% of Regimen-C patients and 50% of Regimen-DI patients ( P = .003,   2  test). There was 
no evidence of a difference in overall survival (hazard ratio [HR] = 0.94, 95% CI = 0.71 to 1.24;  P = .64) or 
pro gression-free survival (HR = 0.98, 95% CI = 0.77 to 1.24;  P = .83). Landmark analyses showed similar results. 
  Conclusions  Planned intensification of chemotherapy with cisplatin and doxorubicin increased received dose intensity 
and resulted in a statistically significant increase in favorable histologic response rate, but not in increased 
progression-free or overall survival. Our results call into question the use of histologic response as a sur-
rogate outcome measure in trials of this disease. 
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 CONTEXT AND CAVEATS 
 Prior knowledge 
 Chemotherapy has improved outcomes for patients with osteosar-
coma such that 50% – 70% of them are alive 5 years after diagnosis. 
However, in recent trials, treatments in which the number of che-
motherapeutic agents or the duration of chemotherapy was 
increased did not improve patient survival compared to conven-
tional chemotherapy. 
 Study design 
 This is a randomized clinical trial comparing two treatment regi-
mens with overall and progression-free survival as the clinical 
endpoints. 
 Contribution 
 This trial investigated whether increasing the planned dose inten-
sity of the chemotherapeutic agents cisplatin and doxorubicin 
would improve outcomes compared to conventional treatment 
with these drugs. The investigators found that increased dose 
intensity, while improving histologic response, did not prolong 
patient survival. 
 Implications 
 Testing of additional therapeutic strategies will be required to improve 
survival of patients with osteosarcoma, and histologic response 
may not be a valid surrogate outcome in osteosarcoma trials. 
 Limitations 
 Due to the rarity of osteosarcoma, this trial took a long time to 
recruit and mature, and it involved many countries with different 
standard approaches to chemotherapy and surgery. 
 During the last three decades, 5-year survival of patients with 
localized high-grade osteosarcoma has risen from less than 20% to 
50% – 70%, and parallel advances in conserving surgical techniques 
have led to limb salvage rates of more than 75% ( 1 ). These 
improved outcomes followed the introduction of effective adju-
vant and neoadjuvant chemotherapy ( 2 – 11 ). At present, the four 
principal active drugs for osteosarcoma are cisplatin ( 12 , 13 ), doxo-
rubicin ( 14 ), high-dose methotrexate ( 15 , 16 ), and ifosfamide 
( 17 , 18 ), but the most effective combination of these agents is un -
known ( 4 – 11 ). 
 The European Osteosarcoma Intergroup (EOI) was formed in 
1982 to conduct randomized controlled trials for patients with 
osteosarcoma. The fi rst EOI randomized controlled trial (Medical 
Research Council [MRC] BO02, European Organization for 
Research and Treatment of Cancer [EORTC] 80831) ( 6 ) com-
pared six cycles of a two-drug regimen (cisplatin and doxorubi-
cin) ( 19 ) with four cycles of a three-drug regimen (cisplatin, 
doxorubicin, and high-dose methotrexate). In 198 patients with 
primary nonmetastatic limb osteosarcoma, the two-drug regimen 
was associated with a statistically signifi cant increase in progression-
free survival at 5 years (57% versus 41%, hazard ratio [HR] = 0.63 
(95% confi dence interval [CI] = 0.42 to 0.94). The second EOI 
randomized controlled trial (MRC BO03, EORTC 80861) ( 7 ) 
compared an 18-week, two-drug regimen consisting of cisplatin 
and doxorubicin with a 47-week multidrug regimen consisting of 
high-dose methotrexate, doxorubicin, cisplatin, bleomycin, cyclo-
phosphamide, and actinomycin-D that was based on the Rosen 
T-10 protocol ( 18 ). Between 1986 and 1993, 391 eligible patients 
with primary nonmetastatic limb osteosarcoma were randomly 
assigned to these two treatments. No difference was observed in 
progression-free survival (HR = 1.01, 95% CI = 0.77 to 1.33) or 
overall survival, with 5-year progression-free survival and overall 
survival of 44% and 55%, respectively, in both arms. 
 In experimental animal models for the treatment of chemosen-
sitive tumors, most cytotoxic drugs exhibit a sigmoidal dose –
 response curve ( 20 ) with lag, linear, and plateau phases. Increasing 
total dose or dose intensity such that drug concentration increases 
to higher values within the linear phase of the dose – response curve 
should minimize drug resistance and maximize effective cell kill 
( 21 ). In the clinical setting, the nature of dose – response curves are 
unknown, and, in particular, the slopes of the linear phase and the 
plateau doses have not been determined. 
 Clinical studies in various adult and childhood malignancies 
indicated that dose intensity may be important in determining 
survival: retrospective studies in breast cancer ( 22 ), Hodgkin lym-
phoma ( 23 ), non-Hodgkin lymphoma ( 24 , 25 ), and neuroblastoma 
( 26 ) showed a positive association between planned dose intensity 
and survival in conventional dosing schedules. Evidence as to 
whether increasing planned dose intensity above conventional lev-
els by dose compression improves outcome has been evolving in a 
number of malignancies ( 27 – 30 ). More recently, this concept of 
increasing dose intensity has been referred to as  “ dose density. ” 
The hypothesized advantage of dose-dense chemotherapy is that 
compressing conventional schedules of drug administration can 
achieve greater effi cacy by minimizing regrowth of tumor cells 
between treatment cycles ( 31 ). 
 Several retrospective studies have identifi ed dose intensity as a 
potentially important determinant of outcome in patients treated 
for osteosarcoma. In a review of 16 studies, Smith et al. ( 32 ) found 
a strong relationship between planned doxorubicin dose intensity 
and histologic tumor necrosis. Other retrospective studies con-
cluded that doxorubicin dose ( 33 ) or planned high-dose metho-
trexate intensity ( 34 , 35 ) infl uenced outcome. The EOI investigated 
the impact of received dose intensity on the conventional two-
drug cisplatin and doxorubicin regimen given every 3 weeks ( 36 ). 
This retrospective analysis of trial data failed to demonstrate any 
benefi t for those patients who received this regimen most inten-
sively. However,  both overall survival and progression-free sur-
vival were lowest for patients receiving the lowest dose intensity, 
and progression-free survival was lower for those who received 
between one and fi ve treatment cycles compared to those who 
received all six cycles. 
 Previous EOI trials showed no additional benefi t from increasing 
the number of agents or length of treatment, and therefore, the 
two-drug cisplatin and doxorubicin remained our standard. It was 
hypothesized that a further increase in the planned dose intensity of 
cisplatin and doxorubicin would improve outcome. A pilot study 
demonstrated the feasibility of increasing the dose intensity of the 
two-drug regimen by 50%, by using granulocyte colony-stimulating 
factor (G-CSF) to shorten the treatment cycle from 3 to 2 weeks 
( 37 ). This demonstration has formed the basis of the trial (MRC 
BO06/EORTC 80931) reported here. To our knowledge, this is the 
fi rst randomized trial of the effectiveness of increased dose intensity 
in the treatment of high-grade osteosarcoma. 
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 P atients and M ethods 
 Trial Design 
 This was an open-label randomized controlled trial with the 
primary outcome measure of overall survival (time to death from 
any cause) and a secondary outcome measure of progression-free 
survival, i.e., time to nontumor death or any relapse or recurrence 
including distant metastases (but not including local disease pro-
gression before primary surgery). For the trial, 165 events were 
planned to detect an improvement of 15% in 5-year survival 
(55% – 70%, HR = 0.6) with 90% power and a two-sided statistical 
significance level of 5%. Randomizations were performed sepa-
rately and centrally at the two trials offices (Medical Research 
Council Clinical Trials Unit [MRC CTU] and EORTC Data 
Center). Minimization was performed with two stratification 
 factors: center and age (0 – 16 or ≥17 years). 
 Patients 
 Patients aged 40 years or less with a histologically confirmed diag-
nosis of high-grade osteosarcoma in an extremity long bone ( 38 ) 
were eligible for the trial ( 39 , 40 ). An EOI pathologist reviewed each 
diagnosis and assigned histologic subtype. Patients with paraosteal, 
periosteal, Paget-related, or radiation-induced osteosarcoma were 
ineligible. Also excluded were patients with prior malignancy, any 
chemotherapy before trial entry, reduced glomerular filtration rate 
(<60 mL/min/1.73 m 2 ), cardiac dysfunction, or raised bilirubin. In 
addition, to be eligible, patients needed to commence chemotherapy 
within 28 days after biopsy, with normal leukocyte ( ≥ 3.5 × 10 9 /L) 
and platelet ( ≥ 100 × 10 9 /L) counts. Informed consent was obtained 
according to local requirements. 
 Initial staging investigations included plain radiography of 
tumor and chest, computerized tomography (CT) or magnetic 
resonance image of affected limb, CT scan of thorax, and isotope 
bone scan. Patients with demonstrable metastases were ineligible, 
but equivocal radiology results without confi rmed metastases did 
not render patients ineligible. 
 Patients had full assessment at diagnosis of hematologic and bio-
chemical parameters. This assessement included determination of 
hemoglobin levels, total and differential white blood cell counts, 
platelet counts, and examination of blood fi lm. Plasma levels of cre-
atinine, urea, sodium, potassium, chloride, calcium, magnesium, and 
phosphate were determined. Liver function tests included measure-
ment of bilirubin and alkaline phosphatase and transaminase 
activity. Renal function was assessed by either  51 chromium-EDTA 
or  51 chromium-DTPA isotopic renal clearance. Audiometry was 
performed according to local practice. Cardiac function was assessed 
by echocardiogram or an equivalent test. 
 Quality Assurance 
 The trial was run from the MRC CTU, London, United Kingdom 
(formerly MRC Cancer Trials Office, Cambridge, United Kingdom) 
and the EORTC Data Center, Brussels, Belgium. Data were collated 
for analysis at MRC CTU. The trial was overseen by the Trial 
Management Group and reviewed on three occasions by an indepen-
dent Data Monitoring Committee. No formal stopping rules were 
specified. On the occasion of each review, the Data Monitoring 
Committee recommended that the trial continue. This trial was con-
ducted in compliance with the Declaration of Helsinki, and the pro-
tocol was approved by the appropriate Research Ethics Committees. 
 Chemotherapy 
 As planned, the conventional two-drug regimen (Regimen-C) con-
sisted of six 3-week cycles, each commencing with administration of 
doxorubicin (25 mg/m 2 ) by 4-hour infusion (repeated on days 2 and 
3) and cisplatin (100 mg/m 2 ) by 24-hour infusion, with surgery 
planned between cycles 2 and 3. Regimen-DI consisted of six cycles 
of treatment with the same doses of cisplatin and doxorubicin as in the 
conventional regimen, but with cycles planned to commence every 
2 weeks. Patients treated with this regimen were supported by G-CSF 
(5  μ g/kg daily) by subcutaneous injection on days 4 – 13 of each cycle). 
Surgery was planned between cycles 3 and 4. For both regimens, cis-
platin infusion was preceded by 4 hours of predehydration followed 
by a 24-hour posthydration schedule, which included a forced man-
nitol diuresis. It was recommended that cisplatin be given as a 24-
hour infusion diluted in isotonic saline with added potassium chloride 
and mannitol. In both arms, the surgery window was 14 days in dura-
tion. G-CSF was lenograstim (Amgen, United Kingdom) or filgras-
tim (Chugai, United Kingdom) according to local arrangements. The 
complete schedules for both regimens are shown in  Fig. 1 . 
 Toxicity Monitoring and Dose Modification.  Height (cm), weight 
(kg), surface area (m 2 ), glomerular function, and levels of creatinine, 
sodium, potassium, calcium, magnesium, chloride, phosphates, 
alkaline phosphatase, bilirubin, and transaminases were determined 
before each cycle according to local practice. Blood counts were 
obtained before each cycle and at the expected nadir of the count 
(day 10 in Regimen-C, day 8 in Regimen-DI). Doses could be 
delayed or reduced according to specific criteria as follows: Dose 
reductions of 20% were advised for patients with febrile neutrope-
nia requiring antibiotics or platelet transfusion. Delay was advised 
where neutrophil counts were less than 1 × 10 9 /L and/or platelets 
were less than 100 × 10 9 /L, amended in 1997 to platelets 75 × 10 9 /L. 
Toxicity was graded using the World Health Organization (WHO) 
toxicity coding scheme ( 41 ). Delay or dose reduction was advised 
for renal toxicity or mucositis (WHO grade 3 – 4 in both cases). 
Discontinuation of cisplatin was advised if the glomerular filtration 
rate fell below 60 mL/min/1.73 m 2 for more than 1 week or if grade 
3 – 4 neurotoxicity or symptomatic ototoxicity was observed. Cardiac 
function was assessed by echocardiogram or equivalent before 
treatment and before cycles 3 – 6. The Children’s Cancer Study 
Group anthracycline administration guideline ( 42 ) was adopted 
during the trial to provide more consistency to the management of 
doxorubicin-induced cardiotoxicity. 
 Calculation of Dose Intensity.  Preoperative, postoperative, and 
overall dose intensity were each calculated for cisplatin and doxoru-
bicin according to the protocol expectations for Regimen-C and 
Regimen-DI using the formula 
Dose intensity =     
 Actual dose given/Expected dose given
 Actual duration of chemotherapy/Expected duration of chemotherapy
 Calculation of expected dose and time was based on protocol 
doses with adjustments made for reported changes in body surface 
area during treatment, as indicated by measurements conducted 
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before each cycle was administered. In these calculations, the length 
of the fi nal cycle was considered to be the full expected length (not 
the time to the last dose) to refl ect recovery time. Preoperative time 
was taken as the period from the start of chemotherapy until the 
day of surgery or, if surgery was not performed, until the end of last 
cycle. Postoperative time was taken as the period from the start of 
postoperative chemotherapy until its completion. Overall duration 
was calculated in two ways: as the full duration from the start of 
chemotherapy until the end of chemotherapy including the surgical 
period or similarly but excluding the surgical period. 
 Surgery 
 Patients were clinical and radiologically assessed for response in the 
week before surgery. Local progression was defined as increase in 
tumor size or worsening pain and systemic progression as the devel-
opment of distant metastases. Patients with local progression alone 
were advised to have surgery and continue on protocol; the appear-
ance of metastases was deemed a progression-free survival event, 
and such patients were treated off protocol. 
 Surgery was planned for day 42 in both arms or as soon there-
after as hematologic recovery allowed. Decisions about the type of 
planned surgery, i.e., limb sparing or amputation, were made by 
clinical teams. Surgical margins were defi ned as radical, wide, mar-
ginal, or intralesional. Further details about surgery will be 
published separately. 
 Histologic Response Assessment 
 Resected tumor specimens were assessed for histologic response to 
preoperative chemotherapy ( 43 ). Using the definitions employed 
in the two previous EOI trials, tumor necrosis more than 90% was 
defined as  “ good ” histopathologic response; 10% or more viable 
tumor after chemotherapy was defined  “ poor ” . As tumors with a 
substantial chondroblastic component are intrinsically less respon-
sive to chemotherapy, the extent of chondroblastic differentiation 
was assessed using a standard method of microscopic examination 
to stratify cases. Tumors in which there was more than 30% vol-
ume of chondroblastic differentiation relative to tumor volume 
were defined as chondroblastic. Specimens were reviewed centrally 
by EOI pathologists wherever possible. 
 End of Treatment and Off-treatment Monitoring 
 Full radiologic and toxicity assessment was advised following com-
pletion of treatment. Investigators were advised to perform clinical 
follow-up with chest radiography monthly for the first 6 months 
after treatment, every 2 months until the end of year 1, every 3 
months during year 2, every 4 months during year 3, and every 6 
months until year 5. After 5 years, follow-up was annual. Cardiac 
function was assessed at 1, 3, and 5 years by echocardiography or 
equivalent local practice. 
 Statistical Analyses 
 Analyses were performed on a modified intention-to-treat basis: all 
patients were included in the analysis except for patients determined 
to be histologically ineligible during central pathology review, 
which was performed without reference to treatment allocation. 
These patients were excluded because it was independently con-
firmed that they were ineligible before randomization and should 
not have been entered. Patients who were found after random 
Fig. 1. Schedule of drug treatment and surgery and planned dosage in 
the trial. A) Schedule of drug treatment cycles and surgery for the con-
ventional regimen (Regimen-C) and the dose-intensive regimen 
(Regimen-DI) that were compared in the trial. B) Schedule of drug 
doses within each cycle. In both regimens, C = administration of cispla-
tin as a 100 mg/m2 24-hour infusion, D = administration of doxorubicin as a 
25 mg/m2 4-hour intravenous infusion, and G = granulocyte colony-
stimulating factor (GCSF) given as a 5 µg/kg injection. Cisplatin infusion 
was preceded by 4 hours of predehydration followed by a 24-hour 
posthydration schedule, which included a forced mannitol diuresis. 
C) Planned total doses of each drug according to regimen in preoperative, 
postoperative, and full period of treatment.
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assignment to have violated other eligibility criteria were included 
in the analysis because such assessment was not blind to treatment 
allocation. Baseline characteristics of the patients and their tumors 
were described but not formally tested for differences across arms. 
 All tests were two-sided. No formal adjustments were made for 
multiple testing. Confi dence intervals were calculated at the 95% 
level. Histologic response to preoperative chemotherapy was 
quantifi ed using the chi-square test for association and toxicities 
using relative risks (RRs). Time-to-event data were summarized 
using hazard ratio and Kaplan – Meier plots and compared with 
log-rank tests. All comparisons including relative risks and hazard 
ratios were relative to Regimen-C; therefore, a hazard ratio of less 
than 1.0 indicated an advantage of Regimen-DI. For time-to-event 
calculations, time was from randomization unless specifi ed. 
Adjusted hazard ratios were obtained using Cox regression models; 
the assumption of proportionality was checked both visually and by 
using tools in the Stata software. Tests for heterogeneity of effect 
across groups were tested with chi-square tests for interaction. 
Statistical analyses were performed using Stata 9 software (Stata 
Corporation, College Station, TX). 
 Exploratory and Landmark Analyses.  The purpose of the land-
mark analyses was to allow for comparison of treatment arms 
accounting for histologic response, which was not known until after 
surgery, the primary treatment, had been performed. For patients 
included in the landmark analyses, both surgical details and histo-
logic response had to be ascertained and time was taken as starting 
from 60 days after randomization at which time surgery should 
have been performed and histologic response known. Histologic 
response was unobtainable for some patients. Therefore, explor-
atory survival models were constructed using the landmark approach 
to look at how histologic response (good, poor, unobtainable, or no 
surgery) affected outcome. Additionally, a series of univariate and 
multivariable Cox regression models were constructed to examine 
the effect of overall and preoperative dose and dose intensity on 
overall survival. Finally, sensitivity analyses were performed on 
overall survival and progression-free survival for the whole popula-
tion of all 504 randomly assigned  patients including those patients 
excluded for reasons of prerandomization ineligibility. 
 R esults 
 Accrual, Patient Characteristics, and Follow-up 
 Between May 1, 1993, and September 30, 2002, 504 patients with 
presumed nonmetastatic operable osteosarcoma were enrolled — 292 
through the MRC CTU (United Kingdom, Argentina, and Chile) 
Fig. 2. Trial fl ow diagram (Consolidated Standards of Reporting Clincial Trials [CONSORT] diagram).
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and 212 through the EORTC (including Netherlands, Saudi 
Arabia, Belgium, and Denmark) (full details are presented in the 
Appendix). A Consolidated Standards of Reporting Trials 
flow diagram of the trial is presented in  Fig. 2 . Pathologic review 
identified seven patients as ineligible due to inappropriate histo-
logic diagnoses, and these were excluded from further analyses. 
Therefore, 497 patients (245 assigned to Regimen-C and 252 
assigned to Regimen-DI) were analyzed, including 36 patients who 
were not centrally reviewed. Seven patients were found to not 
fulfill eligibility criteria after random assignment (three due to the 
presence of metastases, three because their osteosarcoma was at an 
incorrect site, and one due to renal insufficiency) but were included 
in the analyses. The baseline characteristics of the 490 eligible 
patients are shown in  Table 1 . More than 60% were 16 years old or 
younger, and 60% were male. Distal femur was the most common 
site of osteosarcoma. Common-type osteosarcoma was the most 
frequent histologic subtype, followed by chondroblastic osteosar-
coma. Other subtypes occurred infrequently. The treatment groups 
were balanced in terms of tumor site, location within the bone, and 
a combination of site and location (data not shown). 
 With reverse Kaplan – Meier censoring ( 44 ), median follow-up 
time was 62 months (range 0 – 126 months). Of the patients last 
reported alive, 91%, 68%, and 44% had follow-up of  ≥ 1, 3, and 
5 years, respectively. The corresponding percentages were similar in 
 Table 1 .  Baseline characteristics * 
 Baseline characteristic 
Allocated treatment
Regimen-C Regimen-DI  Overall 
N % N % N % 
 Eligibility †  
 Eliglible 241 96 249 98 490 97 
  Ineligible — pathology 4 2 1 0 5 1 
  Ineligible — other 4 2 3 1 7 1 
  Ineligible — pathology and other 1 0 1 0 2 0 
 Sex ‡ 
  Male 144 60 149 59 293 59 
  Female 98 40 103 41 201 41 
 Age (y) 
  £ 16 158 64 161 64 319 64 
  >16 87 36 91 36 178 36 
  Median (quartiles) 15 (12 – 18) 15 (13 – 18) 15 (12 – 18) 
  Minimum/maximum 4/38 5/41 4/41
 Site 
  Femur 143 59 153 61 296 60 
  Tibia 60 25 56 22 116 24 
  Fibula 13 5 12 5 25 5 
  Humerus 22 9 26 10 48 10 
  Radius 3 1 2 1 5 1 
  Ulna 0 0 1 0 1 0 
  Missing 4  – 2  – 6  – 
 Location within bone 
  Proximal 93 39 97 39 190 39 
  Midshaft 8 3 4 2 12 2 
  Distal 139 58 149 60 288 59 
  Missing 5  – 2  – 7  – 
 Pathology 
  Common type 131 60 152 68 283 64 
  Chondroblastic 25 12 26 12 51 12 
  Fibroblastic 9 4 6 3 15 3 
  Osteoclast rich 2 1 7 3 9 2 
  Anaplastic 9 4 12 5 21 5 
  Small cell osteo 3 1 2 1 5 1 
  Telangiectatic 22 10 7 3 29 7 
  Other type 16 7 12 5 28 6 
  Missing § 28  – 28  – 56  – 
 Total included 245 100 252 100 497 100 
  Ineligible 5  – 2  – 7  – 
 Total randomly assigned 250  254  504  
 *  Regimen-C = conventional regimen; Regimen-DI = dose-intensive regimen. Percentages may not add to 100% because of rounding. 
 † Randomly assigned patients were excluded only if determined not to meet the pathology criteria on central pathology review. 
 ‡ Sex was missing for three patients on Regimen-C. 
 § Histology was determined on central pathology review using the initial biopsy sample or the resected specimen. No samples were available for 43 patients. One 
or both of these were available for 461 (91%) of randomly assigned patients. In 10 of these patients, the material could not be assessed, and class was not avail-
able for 10 further patients. Patients were included in the analyses unless they were shown to be pathologically ineligible. Therefore, 497 patients are included. 
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n(risk)
Reg-C 238 (4) 234 (16) 218 (5) 213 (11) 202 (33) 169 (132) 37 (30) 7 (3) 4
Reg-DI 246 (4) 242 (12) 230 (12) 218 (30) 188 (130) 58 (49) 9 (8) 1 (0) 1
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Fig. 3. Kaplan–Meier analysis of time from randomization to trial 
milestones. The proportion of patients in the conventional regimen 
(Regimen-C [solid line]) and the dose-intensive regimen (Regimen-DI 
[dashed line]) not yet having completed chemotherapy (A) and not yet 
having completed surgery if surgery was eventually performed (B) are 
shown. Surgery was expected at 42 days.
both treatment groups. Deaths and progression-free survival events 
were reported in 193 (39%) and 272 (55%) patients, respectively. 
 Chemotherapy 
 Among eligible patients, 486 (98%) started trial chemotherapy, 
most within 1 day of random assignment.  Figure 1 shows preopera-
tive and postoperative chemotherapy cycles of Regimen-C (control 
regimen) and regiment-DI (dose-intensive regimen) and the 
planned schedule of doses (of cisplatin, doxorubicin, and G-CSF) 
within a cycle for the two regimens. The planned number of pre-
operative cycles was administered to 170 (69%) and 195 (77%) 
patients allocated to Regimen-C and Regimen-DI, respectively, 
and 192 (78%) and 201 (80%) patients received six cycles of 
Regimen-C and Regimen-DI, respectively ( Table 2 ). The majority 
(80%) of patients stopped chemotherapy on completion of the pro-
tocol treatment, although 24 (10%) and 25 (10%), in Regimen-C 
and Regimen-DI, respectively, stopped prematurely due to exces-
sive toxicity or patient choice. Three deaths occurred during the 
protocol treatment period, all among patients allocated to Regimen-
DI. One patient who died received a very large, nonprotocol dose 
of cisplatin during cycle 1. G-CSF was administered to 20 (8%) of 
patients undergoing Regimen-C and to 244 (99%) of patients 
undergoing Regimen-DI.  Figure 3 , A, depicts time to stopping trial 
chemotherapy and shows how the time of chemotherapy was 
shorter for patients allocated Regimen-DI. 
 Nearly all (468 or 97%) the patients who had chemotherapy 
experienced severe (grade 3 – 4) toxicity ( Table 3 ). Regimen-DI was 
 Table 2 .  Chemotherapy and surgery data * 
 Chemotherapy 
and surgery 
Allocated treatment
Regimen-C Regimen-DI 
N % N % 
 Given intended 
  number of cycles 
  Preoperatively 170 69 195 77 
  Postoperatively 137 54 174 71 
  Overall 192 78 201 80 
 Reason for terminating 
  chemotherapy 
  Treatment completed 189 79 201 82 
  Disease progression 11 5 8 3 
  Excessive toxicity 12 5 17 7 
  Treatment refusal 12 5 8 3 
  Other reason 16 7 10 4 
  Not available 0   – 2   – 
 Histologic response† 
  Good response 71 36 103 50 
  Poor response 128 64 101 50 
  Response unknown 22   – 28   – 
  Surgery not reported 24   – 20    – 
 Surgery performed 
  Limb salvage 164 74 170 73 
  Amputation 38 17 46 20 
  Disarticulation 9 4 10 4 
  Rotation plasty 10 5 6 3 
  No surgery reported 24   – 20   – 
 Total included 245 100 252 100 
 *  Regimen-C = conventional regimen; Regimen-DI = dose-intensive regimen.
 †  Good response is  ≤ 10% viable tumor; poor response is >10% viable tumor. 
associated with lower risk of severe leucopenia (RR = 0.85, 95% CI = 
0.77 to 0.95) and neutropenia (RR = 0.83, 95% CI = 0.76 to 0.89) 
and higher risk of thrombocytopenia (RR = 1.33, 95% CI = 1.17 to 
1.52) and mucositis (RR = 1.30, 95% CI = 0.99 to 1.70). A small 
increase in ototoxicity was reported for patients on Regimen-DI. 
 Table 4 shows the number of, and reasons for, dose reductions of 
20% or greater of either drug and delays longer than 3 days in the 
2639 reported cycles. There were more patients with at least one 
delay on Regimen-DI than on Regimen-C (190 patients on 
Regimen-C versus 227 patients on Regimen-DI,  χ2
1
 = 15.71, 
 P <.001) and more delayed cycles on the intensive regimen (685 
delayed cycles in Regimen-DI versus 420 delayed cycles in 
Regimen-C ( χ2
1
 = 84.33,  P <.001). Hematologic toxicity was reported 
to cause more delays on Regimen-DI (205 (15%) delayed cycles 
affecting128 patients) than Regimen-C (104 (8%) delayed cycles 
affecting 68 patients). Dose reductions of cisplatin of more than 
20% occurred in 162 (13%) cycles in Regimen-C and in 146 (11%) 
cycles in Regimen-DI; doxorubicin was reduced in 145 (11%) 
cycles in Regimen-C and in 147 (11%) cycles in Regimen-DI. 
Thus, the dose reduction of the two drugs was similar when 
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compared across the same treatment group. Data pertaining to 
long-term cardiac function will be reported in detail elsewhere. 
 Received Dose and Dose Intensity Analysis 
 Preoperative, postoperative, and overall received dose and relative 
dose intensity of cisplatin and doxorubicin for a given regimen 
were calculated ( Fig. 4 ). We plotted received dose intensity against 
received total dose in individual patients for each drug and allocated 
treatment. Overall, the scatter plots show that Regimen-DI led to 
more higher doses of drug and greater dose intensity preoperatively, 
lower doses of drug but great dose intensity postoperatively, and so 
similar doses of drug but greater dose intensity overall. The clear 
scattering of values in each of the plots shows the deviation from the 
summary figures for each treatment and each phase of treatment. 
 Dose.  The median standardized received cisplatin doses for 
Regimen-C and Regimen-DI were 565/600 (94%) and 593/600 
(99%), respectively, and the median standardized received 
 doxorubicin doses were 428/450 (95%) and 440/450 (98%), respec-
tively ( Table 5 ). Thus, overall, higher total doses of cisplatin and 
doxorubicin were delivered to patients allocated to the intensified 
regimen. The explanation may be that, while in both arms the 
median preoperative received dose for each drug was as planned, 
there was some evidence of greater postoperative dose reductions in 
Regimen-C compared to Regimen-DI. 
 Time.  The median time from the start of chemotherapy to 
surgery was 52 and 56 days for Regimen-C and Regimen-DI, 
respectively. Including the surgical period, patients allocated to 
 Table 3 .  Grade 3 or 4 toxicity during protocol chemotherapy * 
 Type 
Regimen-C Regimen-DI
RR (95% CI) †   2 ,  P value N % N %
 WBC ‡ 193 81 170 69 0.85 (0.77 to 0.95) 9.27, <.001 
 Platelets ‡ 137 58 189 77 1.33 (1.17 to 1.52) 20.42, <.001 
 Neutrophil ‡ 220 92 188 76 0.83 (0.76 to 0.89) 23.44, <.001 
 Nausea 113 48 131 53 1.12 (0.94 to 1.33) 1.50, .22 
 Mucositis 64 27 86 35 1.30 (0.99 to 1.70) 3.69, .06 
 Infection 65 27 61 25 0.91 (0.67 to 1.23) 0.40, .53 
 Neurologic 0 0 2 1   – 1.94, .16 
 Ototoxicity 1 0 7 3 6.8 (0.84 to 54.84) 4.40, .04 
 Cardiac 6 3 2 1 0.32 (0.07 to 1.58) 2.17, .14 
 Any toxicities 232 97 236 96 0.98 (0.95 to 1.02) 0.90, .34 
 * Regimen-C = conventional regimen; Regimen-DI = dose-intensive regimen; WBC = white blood cell. Missing data (Regimen-C, Regimen-DI): WBC 2, 0; platelets 
2, 0; neutrophil 2, 0; nausea 3, 0; mucositis 3, 1; infection 3, 1; neurologic 3, 1; ototoxicity 3, 2; cardiac 3, 1; other toxicities 5, 0; all toxicities 2, 0. 
 † RR = relative risk; CI = confidence interval. 
 ‡ WBC, platelet, and neutrophil toxicity based on nadir counts before, during, and after each cycle. 
 Table 4.  Reported reasons for calculated reductions and delays during treatment * 
 Delays of  ≥ 3 days, No. (%) Cisplatin reduction ≥ 20%, No. (%) Doxorubicin reduction  ≥ 20%, No. (%)
 Deviation type Regimen-C Regimen-DI Regimen-C Regimen-DI Regimen-C Regimen-DI 
 Patients with deviations † 
  At least one cycle affected 190 (80) 227 (92) 69 (29) 70 (28) 64 (27) 70 (28)
  No cycles affected 48 (20) 19 (8) 169 (71) 176 (72) 174 (73) 176 (72)
  Total 238 246 238 246 238 246
 Cycles with deviations ‡ 
  Yes, reason known 200 (16) 343 (25) 127 (10) 130 (10) 113 (9) 132 (10)
  Yes, reason not known 220 (17) 342 (25) 35 (3) 16 (1) 32 (2) 15 (1)
  No 862 (67) 672 (50) 1120 (87) 1211 (89) 1137 (89) 1210 (89)
  Total 1282 1357 1282 1357 1282 1357
 Reasons for deviations § 
  Administrative 15 (8) 25 (7) 3 (2) 6 (5) 1 (1) 6 (5)
  Hematologic 104 (52) 205 (60) 63 (50) 58 (45) 62 (55) 68 (52)
  Renal 4 (2) 4 (1) 6 (5) 10 (8) 1 (1) 0 (0)
  Ototoxicity 1 (1) 4 (1) 6 (5) 8 (6) 0 (0) 0 (0)
  Infection 32 (16) 30 (9) 15 (12) 7 (5) 14 (12) 9 (7)
  Other 36 (18) 66 (19) 19 (15) 14 (11) 23 (20) 31 (23)
  Any combination 8 (4) 9 (3) 15 (12) 27 (21) 12 (11) 18 (14)
  Total 200 343 127 130 113 132
 *  The reasons for deviations are only known where they were reported explicitly; no reasons have been deduced where a reduction or delay was calculated but 
not reported explicitly. Regimen-C = conventional regimen; Regimen-DI = dose-intensive regimen. 
 †  % as percentage of all patients starting chemotherapy. 
 ‡  % as percentage of all cycles administered. 
 §  % as percentage of cycles with known reason delay or reduction. 
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Regimen-C had a median time to completion of 155 days com-
pared to 140 days planned, a relative increase of 10%. Regimen-DI 
had a median time to completion of 126 days compared to 98 days, 
an increase of 29%. Excluding the surgical period, patients allo-
cated to Regimen-C had a median time to completion of 139 days 
compared to 126 days planned, a 10% increase, and Regimen-DI 
had an actual median time to completion of 109 days compared to 
84 days planned, a 30% increase. Overall, the patients in Regimen-DI 
also experienced more delays than did patients in Regimen-C. 
 Dose Intensity.  For purposes of comparison, dose intensities were 
calculated relative to the planned dose intensity for Regimen-C 
(100%) The median preoperative dose intensity achieved on 
Regimen-C was 86% for both cisplatin and doxorubicin and it was 
111% on Regimen-DI for both drugs ( Table 5 ). Thus, there was a 
29% relative increase in actual preoperative dose intensity for 
Regimen-DI compared to the actual preoperative dose intensity of 
Regimen-C. Postoperatively, the median cisplatin dose intensities 
on Regimen-C and Regimen-DI were 82% and 110%, respec-
tively, a relative increase of 34% for Regimen-DI; the median dose 
intensities for doxorubicin were 83% and 111%, respectively, a 
relative 33% increase for Regimen-DI. In most cases observed 
dose intensity was below that planned. Excluding the surgery 
 window, overall dose intensity achieved for cisplatin was 83% in 
Regimen-C and 108% in Regimen-DI, a relative increase of 29%, 
and for doxorubicin it was 83% and 109%, respectively, a relative 
increase of 31%. Thus, in each case, the received chemotherapy for 
Regimen-DI was more dose intensive than for Regimen-C. With 
Regimen-DI, overall dose intensity was 73% for doxorubicin and 
72% for cisplatin of that expected for Regimen-DI protocol. Only 
seven Regimen-DI patients achieved a dose intensity of 150% and 
only 10 Regimen-C patients achieved a dose intensity of 100%. 
The observed reductions in dose intensity were due to reductions 
in treatment dose and delays in administering treatment. 
Fig. 4. Total dose and dose intensity for patients treated with chemo-
therapy for osteosarcoma relative to expectations of the conventional 
regimen. Scatter plots of standardized dose intensity versus standard-
ized total dose of cisplatin (CDDP [A]) or doxorubicin (Dox [B]) for the 
preoperative (top panels), postoperative (middle panels), and the full 
course of treatment (lower panels) achieved for patients on the conven-
tional regimen (Regimen-C [open circles]) or the dose-intensive regi-
men (Regimen-DI [solid circles]). Dose and dose intensity values are 
given as a percent of the expectations of the control regimen. In each 
graph, the top right quadrant defi ned by solid lines marks out patients 
whose dose and dose intensity exceeded 80%. The dashed lines indi-
cate planned dose and dose intensity.
0
50
100
150
200
Reg-C Reg-DI
O
ve
ra
ll C
DD
P 
DI
Overall standardized CDDP dose
Overall CDDP: total dose vs dose intensity, by treatment
0
50
100
150
200
Reg-C Reg-DI
Po
st
-o
p 
CD
DP
 D
I
Post-op CDDP: total dose vs dose intensity, by treatment
0
50
100
150
200
0 50 100 150 200 250 300 0 50 100 150 200 250 300
Reg-C Reg-DI
Pr
e-
op
 C
DD
P 
DI
Pre-op standardized CDDP dose
0 50 100 150 200 250 3000 50 100 150 200 250 300
Post-op standardized CDDP dose
0 50 100 150 200 250 3000 50 100 150 200 250 300
Pre-op CDDP: total dose vs dose intensity, by treatment
0
50
100
150
200
Reg-C Reg-DI
Pr
e-
op
 D
ox
or
ub
ici
n 
DI
Pre-op standardized Doxorubicin dose
Pre-op Doxorubicin: total dose vs dose intensity, by treatment
0 50 100 150 200 250 300 0 50 100 150 200 250 300
0 50 100 150 200 250 3000 50 100 150 200 250 300
0
50
100
150
200
0 50 100 150 200 250 300 0 50 100 150 200 250 300
Reg-C Reg-DI
Po
st
-o
p 
Do
xo
ru
bi
cin
 D
I
Post-op standardized Doxorubicin dose
Post-op Doxorubicin: total dose vs dose intensity, by treatment
0
50
100
150
200
Reg-C Reg-DI
O
ve
ra
ll D
ox
or
ub
ici
n 
DI
Overall standardized Doxorubicin dose
Overall Doxorubicin: total dose vs dose intensity, by treatment
A B
jnci.oxfordjournals.org   JNCI | Articles 121
 Surgery 
 Surgical data were available for 453 (90%) patients. The median 
time to surgery in Regimen-C was 52 days (95% CI = 49 to 54), 
and in Regimen-DI it was 56 days (95% CI = 55 to 57), HR = 
0.89,  P = .20 ( Fig. 3, B ). Limb salvage was the most common 
operation and was performed in 164 (74%) and 170 (73%) 
patients in Regimen-C and regimen-D1, respectively. Of 
patients who had surgery, 84% underwent the planned ope-
ration. There was no evidence of a difference in immediate or 
late postoperative complication rates according to treatment 
regimen. 
 Histologic Response 
 Histologic diagnosis was confirmed in 461 (93%) patients, and 
histologic subtype was assessable in 441 (89%) patients of 
the 497 patients eligible ( Table 1 ). Resected tumor specimens 
were reviewed in 403 (89%) of the 453 trial patients with surgical 
details. Good response was observed in 71 (36%) of the assess-
able Regimen-C patients and 103 (50%) Regimen-DI patients 
(RR = 1.30; 95% CI = 1.09 to 1.54;  χ2
1
 = 9.01,  P = .003). Median 
time to surgery was 56 days in the 229 (57%) good responders 
and 53 days in the 174 (43%) poor responders (HR = 1.26, 
 P = .023). 
 Table 5 .  Summary of total dose and dose intensity by allocated regimen * 
 Regimen-C Regimen-DI 
 Observed Observed 
 Timing Planned Median Quartiles Planned Median Quartiles 
 Preoperative period 
  Duration (days) 42 52 45 – 64 42 56 49 – 64 
  Cisplatin dose 200 200 199 – 218 300 300 289 – 301 
  Cisplatin DI  
   Regimen-C plan 100 † 86 76 – 93 150 † 111 95 – 123 
   Regimen-DI plan  –   –  – 100 ‡ 74 64 – 82 
  Doxorubicin dose 150 150 149 – 184 225 225 217 – 226 
  Doxorubicin DI  
   Regimen-C plan 100 † 86 77 – 94 150 † 111 96 – 124 
   Regimen-DI plan  –   –  – 100 ‡ 74 64 – 83 
 Surgical period  
  Preoperative chemotherapy 
   to surgery § (days)
21 26 23 – 30 14 23 19 – 27 
  Surgery to postoperative 
   chemotherapy || (days)
14 18 14 – 22 14 17 14 – 21 
 Postoperative period  
  Duration (days) 84 87 73 – 98 42 55 48 – 59 
  Cisplatin dose 400 335 288 – 400 300 296 219 – 300 
  Cisplatin DI  
   Regimen-C plan 100 † 82 72 – 93 150 † 110 93 – 121 
   Regimen-DI plan   –   –  – 100 ‡ 73 62 – 81 
  Doxorubicin dose 300 253 217 – 299 225 221 165 – 225 
  Doxorubicin DI  
   Regimen-C plan 100 † 83 73 – 95 150 † 111 93 – 121 
   Regimen-DI plan   –   –  – 100 ‡ 74 62 – 81 
  Overall  
  Duration including surgery (days) 140 155 144 – 168 98 126 112 – 138 
  Duration excluding surgery (days) 126 139 129 – 150 84 109 97 – 120 
 Cisplatin dose 600 565 465 – 600 600 593 493 – 600 
  Cisplatin DI ¶  
   Regimen-C plan 100 † 83 75 – 92 150 † 108 95 – 122 
   Regimen-DI plan   –   –  – 100 ‡ 72 63 – 82 
 Doxorubicin dose 450 428 354 – 449 450 440 373 – 450 
  Doxorubicin DI ¶  
   Regimen-C plan 100 * 83 75 – 92 150 † 109 94 – 122 
   Regimen-DI plan   –  –  – 100 ‡ 73 62 – 81 
 G-CSF dose  – 0 0 – 0  – 9202 (7900 – 10 598) 
 * Regimen-C = conventional regimen; Regimen-DI = dose-intensive regimen; G-CSF = granulocyte colony-stimulating factor. 
 † Compared to expectations of Regimen-C. 
 ‡ Compared to expectations of Regimen-DI. 
 § Time from first day of last preoperative chemotherapy cycle to day of surgery. 
 || Time from day of surgery to first day of postoperative chemotherapy. 
 ¶ Overall dose intensity was calculated using the overall duration including the surgical period; the surgical period was not included in the preoperative or postop-
erative DI calculations. 
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 The proportions of Regimen-C and Regimen-DI patients with 
a good response after two preoperative cycles were 26% (95% 
CI = 20% to 34%) and 14% (95% CI = 3% to 36%). The proportions 
of patients with a good response after three preoperative cycles 
were 40% (95% CI = 26% to 56%) and 45% (95% CI = 38% to 
52%) on Regimen-C and Regimen-DI, respectively. Among the 
11 Regimen-C and the 20 Regimen-DI patients who received four 
preoperative cycles, the proportion with a good response was 64% 
(95% CI = 31% to 89%) and 65% (95% CI = 41% to 85%). Thus, 
the proportion of patients with observed good histologic response 
increased with the number of preoperative cycles. 
 Clinical Outcome Measures 
 Progression-free survival.  Kaplan – Meier estimates of progression-
free survival according to the received treatment were derived 
( Fig. 5, A ). The estimated 5-year progression-free survival rates 
were 39% (95% CI = 33% to 46%) for Regimen-C and 41% (95% 
CI = 34% to 47%) for Regimen-DI (HR = 0.98, 95% CI = 0.77 to 
1.24). There was no evidence of a statistically significant difference 
in progression-free survival between treatment regimens based on 
the log-rank test ( χ 2 = 0.05,  P = .83). 
 In landmark analyses timed from 60 days after randomization 
and including 395 patients, the hazard ratio for progression-free 
survival was 0.82 (95% CI = 0.63 to 1.08; log-rank  χ 2 = 2.06,  P = .15) 
in favor of Regimen-DI ( Fig. 5, B ). Stratifying for histologic 
response (good or poor), the landmark analysis hazard ratio for 
progression-free survival was 0.88 (95% CI = 0.67 to 1.16; log-rank 
 χ 2 = 0.84,  P = .36) in favor of Regimen-DI. Using the landmark time 
and patient group in a Cox model including allocated treatment, 
histologic response, and an interaction term for  allocated treatment 
and histologic response, allocated treatment was not a statistically 
signifi cant determinant of outcome (HR = 1.23, 95% CI = 0.75 to 
2.02) whereas histologic response was prognostic (HR = 2.64, 95% 
CI = 1.69 to 4.12). There was no good evidence of interaction 
Fig. 5. Progression-free survival according to allocated treatment. 
Progression-free survival (PFS) for patients treated with conventional 
regimen (Regimen-C [solid line]) and dose-intensive regimen (Regimen-
DI [dashed line]) was calculated from the time of randomization (hazard 
ratio [HR] = 0.98, 95% confi dence interval [CI] = 0.77 to 1.24) (A) or from 
60 days after randomization (HR = 0.82, 95% CI = 0.63 to 1.08) (B) when 
histologic response was known. C) Progression-free survival for 
patients allocated to Regimen-C (left panel) or Regimen-DI (right panel) 
according to histologic response (good [solid line] or poor [dashed 
line]). Hatch marks denote censoring events. Numbers at risk are 
shown below each graph.
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between these factors ( P = .10). Reported progression at any time on 
Regimen-C and Regimen-DI, res pectively, were as follows: local 
progression 22 (9%) versus 11 (4%), local recurrence 44 (18%) ver-
sus 23 (9%), and distant me tastases 107 (44%) versus 113 (45%). 
Regardless of allocated treatment, patients with good histologic 
response had improved progression-free survival in landmark 
 analyses (compared with patients with poor response, HR = 0.50, 95% 
CI = 0.38 to 0.66,  χ 2 = 23.30,  P <.001), with 3-year and 5-year 
 progression-free survival rates of 60% and 56%, respectively, in 
good-response patients and 38% and 33%, respectively, in poor 
response patients. 
 Overall Survival.  At the time of analysis (February 2005), 193 
deaths had been reported (98 in Regimen-C and 95 in Regimen-
DI). The reported causes of deaths were similar according to allo-
cated treatment with the deaths of 93 patients (95%) on Regimen-C 
and 88 patients (93%) on Regimen-DI attributed to osteosarcoma. 
The other 12 deaths were attributed to treatment, although treat-
ment-related deaths occurred during the protocol treatment 
period for only three patients, all on Regimen-DI. The hazard 
ratio for overall survival was 0.94 (95% CI = 0.71 to 1.24) with no 
evidence of a difference between treatment regimens based on 
Kaplan – Meier estimates ( Fig. 6 , A; log-rank  χ 2 = 0.22,  P = .64). The 
5-year overall survival rates were 55% (95% CI = 48% to 62%) for 
Regimen-C and 58% (95% CI = 51% to 65%) for Regimen-DI. 
 In landmark analyses, 145 of the 395 patients eligible for these 
analyses had died (HR = 0.83, 95% CI = 0.60 to 1.15; log-rank 
 χ 2 = 1.24,  P = .26) in favor of Regimen-DI ( Fig. 6, B ). Kaplan – Meier 
estimates for progression-free survival on both regimens in which 
patients are stratifi ed by histologic response were derived ( Fig. 6, C ). 
Stratifying for good and poor histologic response, the landmark 
analysis hazard ratio for survival was 0.91 (95% CI = 0.66 to 1.26; 
log-rank  χ 2 = 0.31,  P = .58) in favor of Regimen-DI. In a Cox model 
that included allocated treatment, histologic response, and an 
Fig. 6. Overall survival according to allocated treatment. Survival for 
patients treated with conventional regimen (Regimen-C [solid line]) and 
dose-intensive regimen (Regimen-DI [dashed line]) was calculated 
from the time of randomization (hazard ratio (HR) = 0.94, 95% confi -
dence interval [CI] = 0.71 to 1.24) (A) or from 60 days after randomiza-
tion (HR = 0.83, 95% CI = 0.60 to 1.15) (B) when histologic response was 
known. C) Overall survival for patients allocated to Regimen-C (left 
panel) or Regimen-DI (right panel) according to histologic response 
(good [solid line] or poor [dashed line]). Hatch marks denote censoring 
events. Numbers at risk are shown below each graph.
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interaction term for these variables, treatment was not statistically 
important (HR = 0.89, 95% CI = 0.49 to 1.62) and histologic 
response was important (HR = 2.01, 95% CI = 1.20 to 3.38), and 
there was no evidence of interaction between these factors 
( P = .92). Regardless of allocated treatment, patients with good 
histologic response had improved survival over patients with poor 
histologic response (HR = 0.50, 95% CI = 0.36 to 0.70,  χ 2 = 15.52, 
 P = .0001); the 3-year and 5-year survival rates were 78% and 71%, 
respectively, in good-response patients and 63% and 49%, respec-
tively, in patients with poor response. 
 In exploratory landmark analyses using the 487 patients who 
were alive 60 days after randomization, by which time surgery 
should have been performed, those patients who had surgery but 
for whom histologic response was not available had poorer survival 
than both good-response patients (HR = 2.61, 95% CI = 1.53 to 
2.75) and poor-response patients (HR = 1.29, 95% CI = 0.76 to 
2.20). Patients for whom no surgery was reported had even worse 
survival compared with good responders (HR = 4.05, 95% CI = 
1.97 to 8.31) ( Fig. 7, A ). A similar trend was noted for progression-
free survival ( Fig. 7, B ). 
 A series of univariate and multivariate Cox regression models 
based on chemotherapy and outcome data from 485 patients who 
received chemotherapy (one patient with a large overdose was 
excluded) showed no good evidence that received cisplatin dose, 
cisplatin dose intensity, doxorubicin dose, or doxorubicin dose 
intensity (whether preoperative or overall) affected overall sur-
vival. There was a suggestion that increased preoperative and 
overall cisplatin dose may be associated with improved survival: 
each 10% increase in preoperative standardized cisplatin dose was 
associated with an improvement in survival (HR = 0.87, 95% CI = 
0.76 to 0.99) as was each 10% increase in overall standardized cis-
platin dose (HR = 0.88, 95% CI = 0.77 to 1.00). 
 Sensitivity analyses were performed to assess the impact of 
the modifi ed intention-to-treat approach by examining the results 
Fig. 7. Overall and progression-free 
survival (PFS) according to histologic 
response and whether surgery was 
performed. Overall survival (A) and 
progression-free survival (B) were 
 calculated from 60 days after 
 randomization for patients on the con-
ventional regimen (Regimen-C, left 
panels) or the dose-intensive regimen 
(Regimen-DI, right panels) according 
to histologic response (good [solid 
black lines], poor [solid gray lines], or 
unknown [NK; dashed black lines] and 
in cases where surgery was not per-
formed [No surg; gray dashed lines]). 
Numbers at risk are shown below each 
graph.
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of all 504 randomly assigned patients. The hazard ratios for 
 progression-free survival and overall survival in this total popula-
tion were the same as for the modifi ed intention-to-treat popula-
tion (n  = 497) that was analyzed. 
 D iscussion 
 Here, we have presented results for the third EOI randomized 
controlled trial in osteosarcoma. This trial was designed to 
 prospectively test the hypothesis that increasing the planned dose 
intensity of the EOI cisplatin and doxorubicin regimen by a factor 
of 1.5 would improve outcome for patients with nonmetastatic limb 
osteosarcoma. The trial involved 48 centers in 11 countries. In this 
complex setting, we have demonstrated that patients randomly 
assigned to the dose-intensive arm, Regimen-DI, received treat-
ment at increased dose intensity compared to patients in the con-
ventional arm, Regimen-C. Despite the relatively large number of 
patients, 5-year median follow-up, and more events reported than 
were planned, the trial was only powered to detect a relatively large 
15% absolute difference (HR = 0.6) between arms. Consequently, 
the trial had limited power to detect a smaller but still clinically 
relevant benefit of Regimen-DI. With this data an absolute differ-
ence in overall survival of 10% cannot be excluded. 
 Perhaps not surprisingly, patients receiving G-CSF in Regimen-
DI had substantially less grade 3 – 4 neutropenia but statistically 
signifi cantly increased thrombocytopenia compared with patients 
in Regimen-C. Hematologic toxicity was the main reason for 
delays and dose reductions. There were concerns that a dose-dense 
schedule might lead to increases in other acute toxicities, but there 
was no good evidence from this trial to support this possibility, 
except for increases in mucositis and ototoxicity that were of bor-
derline statistical signifi cance. There were also particular concerns 
before the trial that doxorubicin every 2 weeks might provoke 
increased early  cardiotoxicity, but there was no consistent evidence 
of this (data not shown). 
 Overall in this trial, patients receiving Regimen-DI received 
their total treatment at 31% greater intensity relative to those 
receiving Regimen-C — less than the planned 50% increase. As 
expected from clinical experience, the actual intensity of both arms 
was less than planned. In fact, the observed intensity for Regimen-
DI was close to, but more than, the planned intensity for Regimen-
C. Although patients in both arms experienced delays and dose 
reductions, patients allocated to Regimen-C were more likely to 
have their chemotherapy doses reduced because of toxicity. They 
were also more likely than those on Regimen-DI to receive treat-
ment on time. Patients allocated Regimen-DI had close to full-
dose treatment, but with substantially increased delays. There was 
no evidence that dose intensity varied systematically according to 
disease or patient characteristics. 
 Histologic response to chemotherapy has repeatedly been dem-
onstrated to be a major prognostic indicator in osteosarcoma and 
is sometimes used as a surrogate marker of outcome (3235). This 
study confi rmed that patients with good response (>90% tumor 
necrosis) had outcomes that were improved to a statistically signifi -
cant extent compared to those with poor response ( ≥ 10% viable 
cells), with reported 5-year survival of rates 71% and 51%, respec-
tively. This trial also demonstrated a statistically signifi cant 
increase in the rate of good histologic response for Regimen-DI 
over that of Regimen-C (50% versus 36%). However, this advan-
tage in histologic response did not translate into a demonstrable 
survival benefi t. This suggests that histologic response would not 
be a good surrogate measure despite previous indications, and this 
observation demands further exploration. 
 One possible explanation for the fact that histologic response 
was not associated with overall survival is that the association was 
obscured by the results of patients whose histologic response was 
not assessed. In this trial, patients with unknown histologic response 
had worse outcomes than would have been predicted for a randomly 
selected representative group of trial patients ( Fig. 7 ). However, the 
landmark analyses accounted for this by including only patients for 
whom both surgery and histologic response data were available. 
 Most Regimen-DI patients received three cycles of preoperative 
chemotherapy, one cycle more than that received by most Regimen-
C patients, and they received a 50% greater preoperative chemo-
therapy dose. This raises the possibility that histologic response 
might be dependent on dose per se, rather than on dose intensity. 
There is support for this hypothesis because exploratory analyses 
showed similar increases in histologic response rates in both arms 
according to the number of preoperative cycles. Although the 
 proportion of histologic responders increased with increased stan-
dardized preoperative dose, the proportion of responders did not 
show a clear increase with increasing standardized dose intensity. 
These observed trends are not based on a randomized comparison 
and therefore should be treated with caution. 
 The favorable histologic response rate (50%) for Regimen-DI 
in this trial is higher than that seen with cisplatin and doxorubicin 
in previous trials (response rates 30% – 35%) ( 6 , 7 ), even though 
preoperative doses were the same and planned time to surgery was 
shorter (6 versus 9 weeks). Thus, either increasing dose intensity 
has led to increased tumor necrosis or the technical assessment of 
histologic response has changed over time so that increased num-
bers of tumors are deemed to have responded. The latter possibil-
ity seems unlikely given that the methodology was the same as 
that used in previous EOI trials (with several of the same refer-
ence pathologists analyzing the data) ( 43 ) and the fact that 
changes in assessment should have affected both trial arms. An 
alternative explanation for the observed increase in favorable his-
tologic response in Regimen-DI is that more intensive chemo-
therapy delivery alters sensitivity and specifi city of the histologic 
response assessment so that despite the appearance of good histo-
logic response, greater numbers of cells survive. Progression-free 
survival for patients with good histologic response was slightly 
less in Regimen-DI than in Regimen-C and for poor responders 
slightly better ( Fig. 5, C ), suggesting that the interpretation 
of good response may be different for patients receiving the 
dose-intensive schedule. Certainly, these results challenge the 
emphasis placed on histologic response as the key treatment-
related prognostic factor ( 20 , 45 ) and suggest that the predictive 
value of histologic response may be protocol specifi c. Although 
inappropriate as a surrogate outcome measure, pathological 
response to preoperative chemotherapy is able to select for 
patients with good prognosis. 
 With the completion of this trial, the EOI has carried out 
three randomized controlled trials since 1983, all incorporating a 
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control arm planned to deliver six cycles of  cisplatin and doxorubi-
cin every 3 weeks with surgery after two or three cycles. None of 
the research arms (three drug, multidrug, or dose intensifi ed) have 
demonstrated any statistically signifi cant benefi t over this con-
ventional arm. In this trial, the 5-year progression-free survival 
and overall survival for nonmetastatic high-grade limb osteosar-
coma in the conventional arm were 39% and 55%, respectively. 
These percentages do not compare favorably with outcomes 
reported by other large cooperative groups. Cooperative 
Osteosarkomstudiengruppe (COSS) reported 10-year progres-
sion-free survival of 49% and overall survival of 60% in 1702 
patients entered into all their studies. The COSS trial encom-
passed several randomized controlled trials and included patients 
with axial primaries and metastases ( 46 ). The Children's Oncology 
Group (COG), after conducting the largest multi-institutional 
randomized controlled trial in osteosarcoma and using the three-
drug regimen of cisplatin, doxorubicin, and high-dose methotrex-
ate, reported 3-year progression-free survival and overall survivals 
of 71% and 80%, respectively ( 11 ). Results of broadly similar mag-
nitude have been reported by other multi-institutional groups 
although not in randomized controlled trials ( 45 , 47 ). Comparisons 
across trials and between groups are complex and unreliable, but it 
is diffi cult not to conclude there might be identifi able factors 
accounting for the results from the EOI trials. One difference is 
that other groups have, in general, used longer regimens with 
more drugs. 
 This EOI trial recruited 504 patients over a period of 9 years 
and is the second largest osteosarcoma randomized controlled trial. 
Although this is a relatively large randomized controlled trial in the 
fi eld of osteosarcoma, it clearly has its limitations because of the trial 
size.  EOI has recently joined with other large trials groups (COG, 
COSS, and Scandinavian Sarcoma Group) to form EURAMOS: the 
EURopean  and AMerican OsteoSarcoma group. This is an interna-
tional intergroup aiming to develop and conduct randomized con-
trolled trials pertaining to osteosarcoma and associated studies. 
EURAMOS plans to recruit more than 400 patients per year, and 
the fi rst EURAMOS randomized controlled trial, EURAMOS 1, 
opened to recruitment in 2005 ( 48 ). EURAMOS 1 is using patho-
logic response to stratify patients by risk and then perform separate 
randomizations for good-response and poor-response patients; the 
standard arm in each group uses a three-drug regimen of cisplatin, 
doxorubicin, and high-dose methotrexate; good responders are ran-
domly assigned to continue standard treatment and follow this with 
maintenance therapy with pegylated interferon; poor responders are 
randomly assigned to supplement the cisplatin, doxorubicin, and 
high-dose methotrexate with ifosfamide and etoposide. 
 Our trial had a number of limitations and compromises. We 
had to make a pragmatic decision about the timing of surgery, and 
there were positives and negatives to each of the approaches: either 
choice could have affected the surrogate outcome of histologic 
response to preoperative treatment. The negative is that patients 
did not have a fi xed dose of chemotherapy before surgery, but we 
felt this was outweighed by the positives of ensuring that surgery, 
the primary therapy for these patients, was at a fi xed time on each 
arm and that histologic response was assessed at the same point in 
time. The trial took a long time to recruit and mature. Largely, this 
is because of the rarity of the condition. This has led to the decision 
to participate with other cooperative groups in future trials. The 
multicountry nature of the trial added some diffi culties, especially 
where countries vary in their standard approaches to chemotherapy 
and surgery. In this context, central pathology review was not com-
plete in all cases and data collection was diffi cult to organize. With 
the main participating countries, these were not problematic, but 
data collection and histologic response were more diffi cult to orga-
nize in certain countries which had communication diffi culties. 
 In summary, this was one of the largest trials in osteosarcoma, 
and it tested the use of dose-intensifi ed perioperative chemother-
apy. Both regimens planned the same total chemotherapy doses 
and both planned surgery at day 42. Most patients experienced 
some form of grade 3 or 4 toxicity. Regimen-DI resulted in more 
tumors having good histologic response to preoperative chemo-
therapy, but this did not translate into a demonstrable patient 
benefi t in overall survival or progression-free survival over 
Regimen-C. The emphasis placed on histologic response as the 
key treatment-related predictive factor is thereby challenged ( 20 ). 
Clinical outcomes measures for this patient group need to be 
 further improved. 
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 A ppendix 
 The EOI was formed in 1982 to facilitate suffi ciently sized randomized controlled 
trials. It has had representation from National Cancer Research Institute Sarcoma 
Clinical Studies Group, U.K. Children's Cancer Study Group, Société 
Internationale d’Oncologie Paediatrique (SIOP), and EORTC Soft Tissue and 
Bone Sarcoma Group. 
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